研究業績

論文・出版

Effectiveness of neo-adjuvant systemic therapy with trastuzumab for basal HER2 type breast cancer: results from retrospective cohort study of Japan Breast Cancer Research Group (JBCRG)-C03


Yasuaki Sagara, Masahiro Takada, Yasuyo Ohi, Shoichiro Ohtani, Sasagu Kurozumi, Kenichi Inoue, Yoshimasa Kosaka, Masaya Hattori, Toshinari Yamashita, Shintaro Takao, Nobuaki Sato, Hiroji Iwata, Masafumi Kurosumi, Masakazu Toi


Breast Cancer Res Treat. 2018 Oct;171(3):675-683. doi: 10.1007/s10549-018-4873-0. Epub 2018 Jul 3.

Survival Outcomes of Retreatment with Trastuzumab and Cytotoxic Chemotherapy for HER2-Positive Recurrent Patients With Breast Cancer Who Had Been Treated with Neo/adjuvant Trastuzumab Plus Multidrug Chemotherapy: A Japanese Multicenter Observational Study


Hiroyasu Yamashiro, Masataka Sawaki, Norikazu Masuda, Yasuhiro Okumura, Toshimi Takano, Eriko Tokunaga, Tsuyoshi Saito, Yasuaki Sagara, Kosuke Yamazaki, Yoshihiro Kawaguchi, Tecchuu Lee, Shinji Ozaki, Kazuhiko Yamagami, Naohito Yamamoto, Katsumasa Kuroi, Hirofumi Suwa, Shoichiro Ohtani, Toshikazu Ito, Shinji Yasuno, Satoshi Morita, Shinji Ohno and Masakazu Toi; On behalf of the JBCRG-C02 Collaborative Group


Breast Cancer: Basic and Clinical Research Volume 12: 1-7, 2018. doi: 10.1177/1178223418786243.

Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial


N. Masuda, M. Toi, N. Yamamoto, H. Iwata, K. Kuroi, H. Bando, S. Ohtani, T. Takano, K. Inoue, Y. Yanagita, H. Kasai, S. Morita, T. Sakurai and S. Ohno


Breast Cancer Volume 25, Issue 4, pp 407-415, July 2018. doi: 10.1007/s12282-018-0839-7

Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: a multicenter, open-label, phase II study Short title: Tailored neoadjuvant therapy for breast cancer


Nobuaki Sato, Norikazu Masuda, Takashi Morimoto, Takayuki Ueno, Chizuko Kanbayashi, Koji Kaneko, Hiroyuki Yasojima, Shigehira Saji, Hironobu Sasano, Satoshi Morita, Shinji Ohno, Masakazu Toi


Cancer Medicine2018 Jun 14;7(7):3044-3056. doi: 10.1002/cam4.1600. Online ahead of print.

A multicenter phase II trial of neoadjuvant letrozole plus low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer (JBCRG-07): therapeutic efficacy and clinical implications of circulating endothelial cells


Takayuki Ueno, Norikazu Masuda, Shunji Kamigaki, Takashi Morimoto, Futoshi Akiyama, Masafumi Kurosumi, Hitoshi Tsuda, Yoshiki Mikami, Sunao Tanaka, Satoshi Morita & Masakazu Toi


Cancer Med. 2018 Jun;7(6):2442-2451. doi: 10.1002/cam4.1516. Epub 2018 May 7.

Factors associated with prolonged time to treatment failure with fulvestrant 500 mg in patients with post-menopausal estrogen receptor-positive advanced breast cancer: a sub-group analysis of the JBCRG-C06 Safari study.


Hidetoshi Kawaguchi, Norikazu Masuda, Takahiro Nakayama, Kenjiro Aogi, Keisei Anan, Yoshinori Ito, Shoichiro Ohtani, Nobuaki Sato, Shigehira Saji, Toshimi Takano, Eriko Tokunaga, Seigo Nakamura, Yoshie Hasegawa, Masaya Hattori, Tomomi Fujisawa, Satoshi Morita, Miki Yamaguchi, Hiroko Yamashita, Toshinari Yamashita, Yutaka Yamamoto, Daisuke Yotsumoto, Masakazu Toi, Shinji Ohno


CURRENT MEDICAL RESEARCH AND OPINION, 2018 Jan;34(1):49-54. doi: 10.1080/03007995.2017.1400426

医師主導治験の実施体制整備状況と課題について:乳癌診療施設に対するアンケート調査(JBCRG-Q06)


JBCRG-Q06 坂東裕子、笠井宏委、青儀健二郎、大谷彰一郎、津川浩一郎、森岡由香、山口ひとみ、吉波哲大、橋本郁子、相馬道郎、戸井雅和、増田慎三、大野真司


乳癌の臨床 Vol.32 No. 6 2017 p477-483

A phase I/II pharmacokinetics/pharmacodynamics study of irinotecan combined with S-1 for recurrent/metastatic breast cancer in patients with selected UGT1A1 genotypes (the JBCRG-M01 study)


Hiroshi Ishiguro, Shigehira Saji, Shogo Nomura, Sunao Tanaka, Takayuki Ueno, Masahide Onoue, Hiroji Iwata, Takeharu Yamanaka, Yasutsuna Sasaki, Masakazu Toi


Cancer Medicine, open access, 2017 Dec;6(12):2909-2917. doi: 10.1002/cam4.1258

アンケート調査からみる医師主導治験の課題と展望


笠井宏委、坂東裕子、青儀健二郎、大野真司


CANCER BOARD of the BREAST Vol.3 No.2 p52-53(116-117) 乳癌カレントトピックス、 2017

JBCRGのあらたな取り組み -JCBRGの設立と経緯および臨床試験への取り組み


大野真司


医学のあゆみ Vol.261, No.5, page 572-576, 2017

前のページへ 次のページへ
任意団体JBCRG 研究業績